Cryo-Cell International, Inc. Logo

Cryo-Cell International, Inc.

CCEL

(2.0)
Stock Price

6,17 USD

4.69% ROA

302.44% ROE

19.48x PER

Market Cap.

48.809.134,00 USD

-77243.61% DER

0% Yield

-30.38% NPM

Cryo-Cell International, Inc. Stock Analysis

Cryo-Cell International, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Cryo-Cell International, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-2240.44x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (-77244%), which means it has a small amount of debt compared to the ownership it holds

3 Assets Growth

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

4 ROA

The stock's ROA (4.69%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock appears undervalued (60), presenting an attractive investment chance with its intrinsic value surpassing the current market price.

6 ROE

The stock's ROE indicates a negative return (-324.81%) on shareholders' equity, suggesting poor financial performance.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

9 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

10 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

11 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Cryo-Cell International, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Cryo-Cell International, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

Cryo-Cell International, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Cryo-Cell International, Inc. Revenue
Year Revenue Growth
1996 2.700.000
1997 400.000 -575%
1998 300.000 -33.33%
1999 1.700.000 82.35%
2000 2.109.342 19.41%
2001 5.648.463 62.66%
2002 7.073.094 20.14%
2003 7.549.536 6.31%
2004 12.210.273 38.17%
2005 14.451.331 15.51%
2006 17.180.383 15.88%
2007 17.460.196 1.6%
2008 17.278.058 -1.05%
2009 16.326.684 -5.83%
2010 17.639.576 7.44%
2011 17.918.270 1.56%
2012 17.969.855 0.29%
2013 18.994.614 5.39%
2014 20.126.546 5.62%
2015 21.091.431 4.57%
2016 23.128.047 8.81%
2017 25.384.279 8.89%
2018 29.218.490 13.12%
2019 31.816.571 8.17%
2020 31.147.593 -2.15%
2021 28.884.902 -7.83%
2022 30.336.749 4.79%
2023 31.479.500 3.63%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Cryo-Cell International, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 200.000 100%
1998 400.000 50%
1999 100.000 -300%
2000 275.803 63.74%
2001 51.067 -440.08%
2002 219.659 76.75%
2003 226.679 3.1%
2004 82.509 -174.73%
2005 26.148 -215.55%
2006 486.164 94.62%
2007 545.489 10.88%
2008 194.462 -180.51%
2009 102.414 -89.88%
2010 132.991 22.99%
2011 184.047 27.74%
2012 109.640 -67.86%
2013 36.168 -203.14%
2014 64.367 43.81%
2015 45.780 -40.6%
2016 53.097 13.78%
2017 41.165 -28.99%
2018 91.845 55.18%
2019 30.145 -204.68%
2020 23.851 -26.39%
2021 49.870 52.17%
2022 384.789 87.04%
2023 1.376.528 72.05%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Cryo-Cell International, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 1.500.000
1997 1.800.000 16.67%
1998 1.900.000 5.26%
1999 2.300.000 17.39%
2000 2.853.776 19.41%
2001 3.950.759 27.77%
2002 6.055.754 34.76%
2003 9.712.342 37.65%
2004 6.274.072 -54.8%
2005 9.104.087 31.09%
2006 12.957.465 29.74%
2007 14.462.914 10.41%
2008 10.827.326 -33.58%
2009 8.936.679 -21.16%
2010 9.485.267 5.78%
2011 12.413.082 23.59%
2012 14.426.244 13.95%
2013 11.366.417 -26.92%
2014 12.251.921 7.23%
2015 12.389.452 1.11%
2016 14.722.794 15.85%
2017 13.480.883 -9.21%
2018 15.632.696 13.76%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Cryo-Cell International, Inc. EBITDA
Year EBITDA Growth
1996 1.000.000
1997 -1.700.000 158.82%
1998 -2.200.000 22.73%
1999 -1.400.000 -57.14%
2000 -2.398.313 41.63%
2001 -1.181.130 -103.05%
2002 -2.103.190 43.84%
2003 -5.865.381 64.14%
2004 2.186.783 368.22%
2005 709.740 -208.11%
2006 -3.014.123 123.55%
2007 -4.892.193 38.39%
2008 402.621 1315.09%
2009 3.634.497 88.92%
2010 3.645.378 0.3%
2011 967.044 -276.96%
2012 -1.346.420 171.82%
2013 2.370.927 156.79%
2014 2.231.265 -6.26%
2015 3.178.601 29.8%
2016 2.694.662 -17.96%
2017 5.156.348 47.74%
2018 5.066.626 -1.77%
2019 7.086.017 28.5%
2020 7.642.378 7.28%
2021 5.711.631 -33.8%
2022 6.270.818 8.92%
2023 6.815.244 7.99%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Cryo-Cell International, Inc. Gross Profit
Year Gross Profit Growth
1996 2.400.000
1997 400.000 -500%
1998 100.000 -300%
1999 1.500.000 93.33%
2000 1.282.016 -17%
2001 3.992.415 67.89%
2002 4.577.963 12.79%
2003 4.924.413 7.04%
2004 9.047.316 45.57%
2005 10.308.329 12.23%
2006 11.112.712 7.24%
2007 10.868.051 -2.25%
2008 11.164.544 2.66%
2009 11.794.175 5.34%
2010 13.134.620 10.21%
2011 13.518.826 2.84%
2012 13.081.441 -3.34%
2013 13.672.343 4.32%
2014 14.494.505 5.67%
2015 15.460.566 6.25%
2016 17.353.247 10.91%
2017 18.659.888 7%
2018 20.678.828 9.76%
2019 21.780.396 5.06%
2020 21.490.151 -1.35%
2021 19.895.166 -8.02%
2022 21.544.391 7.66%
2023 22.854.752 5.73%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Cryo-Cell International, Inc. Net Profit
Year Net Profit Growth
1996 600.000
1997 -1.600.000 137.5%
1998 -2.300.000 30.43%
1999 -600.000 -283.33%
2000 -1.490.678 59.75%
2001 899.634 265.7%
2002 -5.327.485 116.89%
2003 -7.521.636 29.17%
2004 2.840.354 364.81%
2005 1.033.406 -174.85%
2006 -2.811.368 136.76%
2007 -5.005.415 43.83%
2008 -760.419 -558.24%
2009 1.424.705 153.37%
2010 3.410.661 58.23%
2011 -2.095.526 262.76%
2012 -6.308.470 66.78%
2013 27.436 23093.4%
2014 553.623 95.04%
2015 8.106.343 93.17%
2016 -1.320.800 713.74%
2017 2.315.100 157.05%
2018 -854.824 370.83%
2019 2.290.774 137.32%
2020 3.624.596 36.8%
2021 2.083.521 -73.96%
2022 2.771.408 24.82%
2023 2.722.244 -1.81%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Cryo-Cell International, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 -1 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 -1 0%
2013 0 0%
2014 0 0%
2015 1 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Cryo-Cell International, Inc. Free Cashflow
Year Free Cashflow Growth
1996 1.100.000
1997 -1.600.000 168.75%
1998 -1.900.000 15.79%
1999 -900.000 -111.11%
2000 -270.892 -232.24%
2001 591.378 145.81%
2002 -936.329 163.16%
2003 -1.860.463 49.67%
2004 2.405.485 177.34%
2005 2.509.451 4.14%
2006 -70.656 3651.65%
2007 -4.073.086 98.27%
2008 321.871 1365.44%
2009 3.119.399 89.68%
2010 1.939.499 -60.84%
2011 224.622 -763.45%
2012 205.357 -9.38%
2013 424.671 51.64%
2014 1.434.304 70.39%
2015 4.742.982 69.76%
2016 4.644.993 -2.11%
2017 5.619.840 17.35%
2018 4.687.167 -19.9%
2019 5.660.912 17.2%
2020 8.016.641 29.39%
2021 974.923 -722.28%
2022 -8.595.812 111.34%
2023 -1.481.932 -480.04%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Cryo-Cell International, Inc. Operating Cashflow
Year Operating Cashflow Growth
1996 1.200.000
1997 -1.000.000 220%
1998 -1.600.000 37.5%
1999 -500.000 -220%
2000 239.530 308.74%
2001 1.257.987 80.96%
2002 201.556 -524.14%
2003 -1.674.114 112.04%
2004 4.647.542 136.02%
2005 3.218.576 -44.4%
2006 924.901 -247.99%
2007 -3.404.396 127.17%
2008 614.163 654.31%
2009 3.747.854 83.61%
2010 2.338.396 -60.27%
2011 819.122 -185.48%
2012 360.901 -126.97%
2013 821.980 56.09%
2014 1.554.821 47.13%
2015 4.851.462 67.95%
2016 4.987.975 2.74%
2017 5.718.173 12.77%
2018 5.333.330 -7.22%
2019 6.323.207 15.65%
2020 8.466.603 25.32%
2021 7.926.094 -6.82%
2022 8.572.647 7.54%
2023 1.942.414 -341.34%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Cryo-Cell International, Inc. Capital Expenditure
Year Capital Expenditure Growth
1996 100.000
1997 600.000 83.33%
1998 300.000 -100%
1999 400.000 25%
2000 510.422 21.63%
2001 666.609 23.43%
2002 1.137.885 41.42%
2003 186.349 -510.62%
2004 2.242.057 91.69%
2005 709.125 -216.17%
2006 995.557 28.77%
2007 668.690 -48.88%
2008 292.292 -128.77%
2009 628.455 53.49%
2010 398.897 -57.55%
2011 594.500 32.9%
2012 155.544 -282.21%
2013 397.309 60.85%
2014 120.517 -229.67%
2015 108.480 -11.1%
2016 342.982 68.37%
2017 98.333 -248.8%
2018 646.163 84.78%
2019 662.295 2.44%
2020 449.962 -47.19%
2021 6.951.171 93.53%
2022 17.168.459 59.51%
2023 3.424.346 -401.36%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Cryo-Cell International, Inc. Equity
Year Equity Growth
1996 3.700.000
1997 3.100.000 -19.35%
1998 2.300.000 -34.78%
1999 5.000.000 54%
2000 6.635.615 24.65%
2001 14.521.268 54.3%
2002 9.569.018 -51.75%
2003 -3.791.009 352.41%
2004 -835.752 -353.6%
2005 394.557 311.82%
2006 -2.092.146 118.86%
2007 -6.590.682 68.26%
2008 -6.978.454 5.56%
2009 -5.180.970 -34.69%
2010 -1.550.568 -234.13%
2011 -2.460.388 36.98%
2012 -8.997.765 72.66%
2013 -9.267.985 2.92%
2014 -10.726.663 13.6%
2015 -4.964.171 -116.08%
2016 -15.414.258 67.79%
2017 -12.502.896 -23.29%
2018 -8.908.298 -40.35%
2019 -6.952.851 -28.12%
2020 -2.665.135 -160.88%
2021 4.184.314 163.69%
2022 -1.524.302 374.51%
2023 -16.163 -9330.81%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Cryo-Cell International, Inc. Assets
Year Assets Growth
1996 4.200.000
1997 4.000.000 -5%
1998 4.100.000 2.44%
1999 5.500.000 25.45%
2000 8.237.368 33.23%
2001 17.394.346 52.64%
2002 13.863.091 -25.47%
2003 7.217.188 -92.08%
2004 11.640.713 38%
2005 14.233.510 18.22%
2006 14.640.383 2.78%
2007 11.633.709 -25.84%
2008 10.972.656 -6.02%
2009 14.608.128 24.89%
2010 18.162.419 19.57%
2011 19.466.744 6.7%
2012 12.330.659 -57.87%
2013 11.500.802 -7.22%
2014 10.209.586 -12.65%
2015 19.497.946 47.64%
2016 19.538.468 0.21%
2017 23.909.997 18.28%
2018 42.390.143 43.6%
2019 42.886.160 1.16%
2020 46.200.094 7.17%
2021 60.662.076 23.84%
2022 64.888.054 6.51%
2023 69.796.366 7.03%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Cryo-Cell International, Inc. Liabilities
Year Liabilities Growth
1996 500.000
1997 900.000 44.44%
1998 1.800.000 50%
1999 500.000 -260%
2000 1.601.753 68.78%
2001 2.873.078 44.25%
2002 3.995.683 28.1%
2003 11.008.197 63.7%
2004 12.476.465 11.77%
2005 13.838.953 9.85%
2006 16.732.529 17.29%
2007 18.224.391 8.19%
2008 17.951.110 -1.52%
2009 19.789.098 9.29%
2010 19.712.987 -0.39%
2011 21.927.132 10.1%
2012 21.328.424 -2.81%
2013 20.768.787 -2.69%
2014 20.936.249 0.8%
2015 24.462.117 14.41%
2016 34.952.726 30.01%
2017 36.412.893 4.01%
2018 51.298.441 29.02%
2019 49.839.011 -2.93%
2020 48.865.229 -1.99%
2021 56.477.762 13.48%
2022 66.412.356 14.96%
2023 69.812.529 4.87%

Cryo-Cell International, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3.77
Net Income per Share
0.3
Price to Earning Ratio
19.48x
Price To Sales Ratio
1.56x
POCF Ratio
6.1
PFCF Ratio
20.57
Price to Book Ratio
-3019.72
EV to Sales
1.94
EV Over EBITDA
9.89
EV to Operating CashFlow
7.58
EV to FreeCashFlow
25.59
Earnings Yield
0.05
FreeCashFlow Yield
0.05
Market Cap
0,05 Bil.
Enterprise Value
0,06 Bil.
Graham Number
0.12
Graham NetNet
-7.63

Income Statement Metrics

Net Income per Share
0.3
Income Quality
3.19
ROE
-3.25
Return On Assets
-0.16
Return On Capital Employed
-0.3
Net Income per EBT
0.71
EBT Per Ebit
1.09
Ebit per Revenue
-0.39
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.03
Stock Based Compensation to Revenue
0.03
Gross Profit Margin
0.73
Operating Profit Margin
-0.39
Pretax Profit Margin
-0.43
Net Profit Margin
-0.3

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
3.06
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.97
Free CashFlow per Share
0.29
Capex to Operating CashFlow
-0.7
Capex to Revenue
-0.18
Capex to Depreciation
-3.22
Return on Invested Capital
0.25
Return on Tangible Assets
0.05
Days Sales Outstanding
75.24
Days Payables Outstanding
119.53
Days of Inventory on Hand
45.61
Receivables Turnover
4.85
Payables Turnover
3.05
Inventory Turnover
8
Capex per Share
-0.68

Balance Sheet

Cash per Share
0,15
Book Value per Share
0,00
Tangible Book Value per Share
-1.97
Shareholders Equity per Share
-0
Interest Debt per Share
1.75
Debt to Equity
-772.44
Debt to Assets
0.18
Net Debt to EBITDA
1.94
Current Ratio
0.54
Tangible Asset Value
-0,02 Bil.
Net Current Asset Value
-0,06 Bil.
Invested Capital
-772.44
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0.23
Average Receivables
0,01 Bil.
Average Payables
0,00 Bil.
Average Inventory
971076.5
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Cryo-Cell International, Inc. Dividends
Year Dividends Growth
2022 1

Cryo-Cell International, Inc. Profile

About Cryo-Cell International, Inc.

Cryo-Cell International, Inc. engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, and auto-immune diseases. The company also manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It stores approximately 500,000 cord blood and cord tissue stem cells worldwide. The company markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. Cryo-Cell International, Inc. was incorporated in 1989 and is headquartered in Oldsmar, Florida.

CEO
Mr. David I. Portnoy
Employee
82
Address
700 Brooker Creek Boulevard
Oldsmar, 34677

Cryo-Cell International, Inc. Executives & BODs

Cryo-Cell International, Inc. Executives & BODs
# Name Age
1 Ms. Jill M. Taymans
Chief Financial Officer & Vice President of Finance
70
2 Mr. Oleg Mikulinsky
Chief Information Officer
70
3 Mr. David I. Portnoy
Chairman & Co-Chief Executive Officer
70
4 Mr. Mark L. Portnoy
Co-Chief Executive Officer & Director
70
5 Dr. Joanne Kurtzberg M.D.
Medical Director and Member of Medical & Scientific Advisory Board
70

Cryo-Cell International, Inc. Competitors